Power morcellators, postmarketing surveillance, and the US Food and Drug Administration

JAMA - Journal of the American Medical Association

Volumn 318, Issue 4, 2017, Pages 325-326

  Redberg, Rita F ^a   Jacoby, Alison F ^b   Sharfstein, Joshua M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECTS; DEVICES; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYSTERECTOMY; LAPAROSCOPY; MYOMECTOMY; POSTMARKETING SURVEILLANCE; PROCEDURES; TUMOR SEEDING; UNITED STATES;

FEMALE; HUMANS; HYSTERECTOMY; LAPAROSCOPY; NEOPLASM SEEDING; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UTERINE MYOMECTOMY;

EID: 85027557428     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.7704     Document Type: Short Survey

References (10)

1. Moore BJ, Steiner CA, Davis PH, Stocks C, Barrett ML. Trends in hysterectomies and oophorectomies in hospital inpatient and ambulatory settings, 2005–2013. https://www.hcup-us.ahrq.gov/reports/statbriefs/sb214-Hysterectomy-Oophorectomy-Trends.pdf. Accessed June 7, 2017.
2. Levitz J, Kamp J. How morcellators simplified the hysterectomy but posed a hidden cancer risk. Wall Street Journal. April 11, 2014. https://www.wsj.com/articles/how-morcellators-simplified -the-hysterectomy-but-posed-a-hidden-cancer-risk-1397269145. Accessed June 8, 2017.
3. Ong MBH. Urgent FDA action turns power morcellator into a rarely used gynecological procedure. https://cancerletter.com/articles/20141126_1/. Accessed June 7, 2017.
4. Parker W, Berek JS, Pritts E, et al. An open letter to the Food and Drug Administration regarding the use of morcellation procedures in women having surgery for presumed uterine myomas. J Minim Invasive Gynecol. 2016;23(3):303-308.
5. Pritts EA, Vanness DJ, Berek JS, et al. The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecol Surg. 2015;12(3):165-177.
6. Ekerhovd E, Wienerroith H, Staudach A, Granberg S. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. Am J Obstet Gynecol. 2001;184(2):48-54.
7. Harris JA, Swenson CW, Uppal S, et al. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation. Am J Obstet Gynecol. 2016;214(1):98.e1-98.e13.
8. Wright JD, Chen L, Burke WM, et al. Trends in use and outcomes of women undergoing hysterectomy with electric power morcellation. JAMA. 2016;316(8):877-878.
9. Reynolds IS, Rising JP, Coukell AJ, Paulson KH, Redberg RF. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies. JAMA Intern Med. 2014;174(11):1773-1779.
10. Broder MS, Kanouse DE, Mittman BS, Bernstein SJ. The appropriateness of recommendations for hysterectomy. Obstet Gynecol. 2000;95(2):199-205.